A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

Andrew H Ko, Patrick B Murphy, James D Peyton, Dianna L Shipley, Ahmed Al-Hazzouri, Francisco A Rodriguez, Mark S Womack 4th, Henry Q Xiong, David M Waterhouse, Margaret A Tempero, Shuangli Guo, Cassie M Lane, Chris Earwood, Laura M DeBusk, Johanna C Bendell, Andrew H Ko, Patrick B Murphy, James D Peyton, Dianna L Shipley, Ahmed Al-Hazzouri, Francisco A Rodriguez, Mark S Womack 4th, Henry Q Xiong, David M Waterhouse, Margaret A Tempero, Shuangli Guo, Cassie M Lane, Chris Earwood, Laura M DeBusk, Johanna C Bendell

Abstract

Lessons learned: The addition of the heat shock protein 27 (Hsp27)-targeting antisense oligonucleotide, apatorsen, to a standard first-line chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer.Findings from this trial hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation.

Background: This randomized, double-blinded, phase II trial evaluated the efficacy of gemcitabine/nab-paclitaxel plus either apatorsen, an antisense oligonucleotide targeting heat shock protein 27 (Hsp27) mRNA, or placebo in patients with metastatic pancreatic cancer.

Methods: Patients were randomized 1:1 to Arm A (gemcitabine/nab-paclitaxel plus apatorsen) or Arm B (gemcitabine/nab-paclitaxel plus placebo). Treatment was administered in 28-day cycles, with restaging every 2 cycles, until progression or intolerable toxicity. Serum Hsp27 levels were analyzed at baseline and on treatment. The primary endpoint was overall survival (OS).

Results: One hundred thirty-two patients were enrolled, 66 per arm. Cytopenias and fatigue were the most frequent grade 3/4 treatment-related adverse events for both arms. Median progression-free survival (PFS) and OS were 2.7 and 5.3 months, respectively, for arm A, and 3.8 and 6.9 months, respectively, for arm B. Objective response rate was 18% for both arms. Patients with high serum level of Hsp27 represented a poor-prognosis subgroup who may have derived modest benefit from addition of apatorsen.

Conclusion: Addition of apatorsen to chemotherapy does not improve outcomes in unselected patients with metastatic pancreatic cancer in the first-line setting, although a trend toward prolonged PFS and OS in patients with high baseline serum Hsp27 suggests this therapy may warrant further evaluation in this subgroup.

Trial registration: ClinicalTrials.gov NCT01844817.

© AlphaMed Press; the data published online to support this summary is the property of the authors.

References

    1. Garrido C, Brunet M, Didelot C et al. Heat shock proteins 27 and 70: Anti‐apoptotic proteins with tumorigenic properties. Cell Cycle 2006;5:2592–2601.
    1. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86–103.
    1. Melle C, Ernst G, Escher N et al. Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem 2007;53:629–635.
    1. Kuramitsu Y, Wang Y, Taba K et al. Heat‐shock protein 27 plays the key role in gemcitabine‐resistance of pancreatic cancer cells. Anticancer Res 2012;32:2295–2299.
    1. Zhang S, Zhang XQ, Huang SL et al. The effects of HSP27 on gemcitabine‐resistant pancreatic cancer cell line through snail. Pancreas 2015;44:1121–1129.
    1. Guo Y, Ziesch A, Hocke S et al. Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S‐phase arrest and apoptosis. J Cell Mol Med 2015;19:340–350.
    1. Kamada M, So A, Muramaki M et al. Hsp27 knockdown using nucleotide‐based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007;6:299–308.
    1. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab‐paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–1703.
    1. Rahib L, Smith BD, Aizenberg R et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913–2921.
    1. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–1825.
    1. Acunzo J, Andrieu C, Baylot V et al. Hsp27 as a therapeutic target in cancers. Curr Drug Targets 2014;15:423–431.
    1. Chi KN, Yu EY, Jacobs C et al. A phase I dose‐escalation study of apatorsen (OGX‐427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration‐resistant prostate cancer and other advanced cancers. Ann Oncol 2016;27:1116–1122.
    1. Choueiri TK, Hahn NM, Pal SK et al. The Borealis‐2 clinical trial: A randomized phase 2 study of OGX‐427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer J Clin Oncol 2014;32; (suppl):TPS4593a.
    1. Spigel DR, Burris HA, Greco FA et al. Double‐blind randomized phase II trial of carboplatin and pemetrexed with or without OGX‐427 in patients with previously untreated stage IV non‐squamous non‐small‐cell lung cancer (NSCLC): The Spruce Clinical Trial J Clin Oncol 2013;31(suppl):TPS8120a.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa